New drug tested to target dangerous belly fat
NCT ID NCT06824051
Summary
This study tested how a new drug called orforglipron changes body fat, especially deep belly fat, in adults with obesity or overweight who do not have diabetes. About 120 participants were randomly assigned to receive either the drug or a placebo (inactive substance) for about 8 months. The main goal was to see if the drug could reduce the amount of harmful visceral fat compared to the placebo.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Axis
Dilworth, Minnesota, 56529, United States
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Ohio Clinical Trials
Columbus, Ohio, 43212, United States
Conditions
Explore the condition pages connected to this study.